Astellas Pharma Inc. ALPMF
16.00 USD -1.40 (-8.05%)
At closeNov 6, 2026, 4:00 PM EST
16.00 Day range 16.00
11.08 52-week range 18.03
- YTD
- +21.49%
- 1 year
- +45.45%
News
benzinga.com Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
benzinga.com These Analysts Boost Their Forecasts On Vir Biotechnology 
benzinga.com What's Going On With Kyntra Bio Stock Tuesday? Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.
benzinga.com Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why Vir Biotechnology stock skyrockets after $335 million Astellas deal, strong prostate cancer data, and upbeat earnings boost outlook.
benzinga.com Why Is Monte Rosa Stock Trading Higher Today? Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.
benzinga.com Why Is Taysha Gene Therapies Stock Falling Friday? Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.
benzinga.com Stocks That Hit 52-Week Highs On Tuesday